[go: up one dir, main page]

HUP0203333A2 - Eljárás benzimidazolalapú vegyületek stabilizálására - Google Patents

Eljárás benzimidazolalapú vegyületek stabilizálására

Info

Publication number
HUP0203333A2
HUP0203333A2 HU0203333A HUP0203333A HUP0203333A2 HU P0203333 A2 HUP0203333 A2 HU P0203333A2 HU 0203333 A HU0203333 A HU 0203333A HU P0203333 A HUP0203333 A HU P0203333A HU P0203333 A2 HUP0203333 A2 HU P0203333A2
Authority
HU
Hungary
Prior art keywords
stabilizing
benzimidazole compounds
crospovidone
benzimidazole
based compound
Prior art date
Application number
HU0203333A
Other languages
English (en)
Inventor
Shigeru Aoki
Satoshi Fujioka
Masao Kawamura
Mitsuru Mizuno
Koji Ukai
Makoto Yokoyama
Original Assignee
Eisai Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co., Ltd. filed Critical Eisai Co., Ltd.
Publication of HUP0203333A2 publication Critical patent/HUP0203333A2/hu
Publication of HUP0203333A3 publication Critical patent/HUP0203333A3/hu
Publication of HU229213B1 publication Critical patent/HU229213B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány tárgya eljárás benzimidazolalapú vegyület vagy ennekfiziológiailag alkalmazható sója stabilizálására orálisan adagolhatószilárd készítmény előállítása érdekében, amelyhez a benzimidazolalapúvegyületet vagy fiziológiailag alkalmazható sóját kroszpovidonnal vagy1) kroszpovidonnal és 2) nátriumhidroxid és káliumhidroxid közülmegválasztott legalább egy komponenssel keverik, és a kapott magotkívánt esetben entereális bevonattal vonják be. Ó
HU0203333A 1999-10-20 2000-10-19 Method for stabilizing benzimidazole compounds HU229213B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP29806399 1999-10-20
PCT/JP2000/007285 WO2001028559A1 (fr) 1999-10-20 2000-10-19 Procede de stabilisation de composes benzimidazoles

Publications (3)

Publication Number Publication Date
HUP0203333A2 true HUP0203333A2 (hu) 2003-02-28
HUP0203333A3 HUP0203333A3 (en) 2004-01-28
HU229213B1 HU229213B1 (en) 2013-09-30

Family

ID=17854666

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203333A HU229213B1 (en) 1999-10-20 2000-10-19 Method for stabilizing benzimidazole compounds

Country Status (19)

Country Link
US (1) US7220762B1 (hu)
EP (1) EP1222922B1 (hu)
JP (1) JP4081273B2 (hu)
KR (1) KR20020038759A (hu)
CN (1) CN1197574C (hu)
AT (1) ATE369857T1 (hu)
AU (1) AU782538B2 (hu)
CA (1) CA2387746C (hu)
CY (1) CY1107506T1 (hu)
DE (1) DE60036014T2 (hu)
DK (1) DK1222922T3 (hu)
ES (1) ES2288876T3 (hu)
HU (1) HU229213B1 (hu)
MX (1) MXPA02003762A (hu)
NO (1) NO329940B1 (hu)
PT (1) PT1222922E (hu)
RU (1) RU2259828C2 (hu)
TW (1) TWI268779B (hu)
WO (1) WO2001028559A1 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004305B1 (en) * 1998-04-20 2011-09-28 Eisai R&D Management Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
AR036354A1 (es) * 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd Preparacion solida
SI21447A (sl) * 2001-11-21 2004-10-31 Eisai Co. Ltd. Sestavek pripravka, ki vsebuje kislinsko nestabilno fiziološko aktivno spojino in postopek priprave le-tega
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
EP1518240B1 (en) 2002-06-28 2014-05-07 LG Electronics, Inc. Recording medium having data structure for managing recording and reproduction of multiple path data recorded thereon and recording and reproducing methods and apparatus
KR100662939B1 (ko) 2002-11-12 2006-12-28 엘지전자 주식회사 기록된 다중 재생 경로 비디오 데이터의 재생을 관리하기위한 데이터 구조를 갖는 기록 매체와 그에 따른 기록 및재생 방법 및 장치
US7720356B2 (en) 2002-11-12 2010-05-18 Lg Electronics Inc Recording medium having data structure for managing reproduction of multiple reproduction path video data recorded thereon and recording and reproducing methods and apparatuses
US7664372B2 (en) 2002-11-20 2010-02-16 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple component data recorded thereon and recording and reproducing methods and apparatuses
TW200503783A (en) * 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
BRPI0509135A (pt) * 2004-03-26 2007-08-28 Eisai R&D Man Co Ltd composição farmacêutica de liberação controlada e método para produzir a mesma
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2007037259A1 (ja) * 2005-09-29 2007-04-05 Eisai R & D Management Co., Ltd. 生体内での崩壊性を向上させたパルス製剤
US20100105738A1 (en) * 2006-10-06 2010-04-29 Mitsuru Mizuno Extended release formulations of a proton pump inhibitor
CN100411613C (zh) * 2006-12-08 2008-08-20 中国药科大学 一种奥美拉唑速释固体制剂及其制备方法
WO2008129517A2 (en) * 2007-04-23 2008-10-30 Ranbaxy Laboratories Limited A stabilized delayed release pharmaceutical composition of rabeprazole
JP5399749B2 (ja) * 2008-03-27 2014-01-29 沢井製薬株式会社 プロトンポンプ阻害剤を含有する被覆微粒子
WO2010117756A2 (en) * 2009-03-31 2010-10-14 Dr. Reddy's Laboratories Ltd Substituted benzimidazole pharmaceutical formulations
US20150209432A1 (en) 2012-07-26 2015-07-30 Lupin Limited Pharmaceutical compositions of proton pump inhibitor
RU2554735C1 (ru) * 2014-08-20 2015-06-27 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция, содержащая рабепразол натрия, и способ ее получения
KR102227486B1 (ko) * 2017-06-30 2021-03-12 롯데정밀화학 주식회사 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB189698A (en) 1921-12-29 1922-12-07 Miniere & Ind Franco Bresilien Method for the treatment of monazite and other phosphate ores
US4471638A (en) * 1982-03-26 1984-09-18 Steelcase Inc. Front removable lock
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
JPS62277322A (ja) 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
ZA871177B (en) 1986-02-21 1988-10-26 Nihon Nohyaku Co Ltd 1,3-diketone derivatives and their use
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
AU619444B2 (en) 1986-06-02 1992-01-30 Nippon Chemiphar Co. Ltd. 2-(2-aminobenzylsulfinyl)- benzimidazole derivatives
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
JPH0656665A (ja) 1992-08-03 1994-03-01 Nippon Chemiphar Co Ltd イミダゾール誘導体を含有する胃溶性抗潰瘍剤
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
PT1078628E (pt) 1994-07-08 2009-01-27 Astrazeneca Ab Forma de dosagem em comprimidos com unidades múltiplas
ES2094694B1 (es) 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
US5708017A (en) 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
US6159499A (en) * 1995-09-21 2000-12-12 Pharma Pass Llc Composition containing an acid-labile benzimidazole and process for its preparation
BE1009764A3 (nl) 1995-11-06 1997-08-05 Dsm Nv Werkwijze voor de bereiding van een alpha-alkylkaneelaldehyde.
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
JPH09216817A (ja) 1996-02-08 1997-08-19 Amano Pharmaceut Co Ltd 防湿性且つ易水崩壊性コーティング製剤
DE69713948D1 (de) 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
AU3191397A (en) 1996-06-25 1998-01-14 Takeda Chemical Industries Ltd. Oxazolone derivatives and their use as anti-(helicobacter pylori) agent
GB9710800D0 (en) * 1997-05-23 1997-07-23 Cipla Limited Pharmaceutical composition and method of preparing it
TW580397B (en) 1997-05-27 2004-03-21 Takeda Chemical Industries Ltd Solid preparation
SE9702000D0 (sv) 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
US6296876B1 (en) 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
US20050244497A1 (en) 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
EP1004305B1 (en) 1998-04-20 2011-09-28 Eisai R&D Management Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20040028737A1 (en) 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same

Also Published As

Publication number Publication date
NO20021875L (no) 2002-06-04
EP1222922B1 (en) 2007-08-15
CN1197574C (zh) 2005-04-20
ES2288876T3 (es) 2008-02-01
PT1222922E (pt) 2007-09-12
DK1222922T3 (da) 2007-12-03
MXPA02003762A (es) 2002-09-30
EP1222922A1 (en) 2002-07-17
NO329940B1 (no) 2011-01-24
CY1107506T1 (el) 2013-03-13
CA2387746A1 (en) 2001-04-26
KR20020038759A (ko) 2002-05-23
TWI268779B (en) 2006-12-21
DE60036014T2 (de) 2008-04-30
US7220762B1 (en) 2007-05-22
CA2387746C (en) 2010-06-29
EP1222922A4 (en) 2006-04-12
RU2259828C2 (ru) 2005-09-10
NO20021875D0 (no) 2002-04-19
CN1382049A (zh) 2002-11-27
ATE369857T1 (de) 2007-09-15
DE60036014D1 (de) 2007-09-27
HUP0203333A3 (en) 2004-01-28
WO2001028559A1 (fr) 2001-04-26
AU782538B2 (en) 2005-08-04
JP4081273B2 (ja) 2008-04-23
AU7950200A (en) 2001-04-30
HU229213B1 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
HUP0203333A2 (hu) Eljárás benzimidazolalapú vegyületek stabilizálására
DK0914119T3 (da) Fremgangsmåde til fremstilling af faste orale dosisformer af valsartan
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
DK1392714T3 (da) Steroider som agonister for FXR
NO20081631L (no) Lav hygroskopisk Aripiprazol medikament forbindelse og fremgangsmate for fremstilling derav
MXPA03006001A (es) Derivados de fosfonato de nucleosido aciclico novedoso, sales de estos y proceso para la preparacion de los mismos.
NO20025821L (no) 2-aminokarbonyl-9H-purinderivater
EE04676B1 (et) Imidasopridiini derivaadid, mis inhibeerivad maohappesekretsiooni, protsess nende valmistamiseks ning nende kasutamine
NO20021042L (no) Benzofenoner som inhibitorer av reverstranskriptaser
GR20020100280A (el) Συνθεση ταχειας ενεργειας
NO20010718D0 (no) Ny saltform av pantoprazol
EA200301276A1 (ru) Новые производные сульфоновых кислот
NO20040881L (no) Orale antidiabetes midler.
PT1105105E (pt) Forma de administracao oral para piridin-2-ilmetilsulfinil-1h-benzimidazois
NO20001514L (no) Vitronectin-reseptor-antagonist
EE04839B1 (et) Heterotsükliline benseensulfoonamiidühend, meetodühendi valmistamiseks, ühendi ja selle liitsoola kasutamine ning neid sisaldav terapeutiline kompositsioon
NO20050664L (no) 2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer
NO20050666L (no) 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer
NO20001515L (no) Vitronektin reseptor-antagonist
EE05187B1 (et) Hirudiini prekursor, selle kasutamine ja meetod Leu-hirudiini valmistamiseks
YU5893A (sh) Sulfonilkarbamid i postupak za njegovo dobijanje
DE69710574D1 (de) Diclofenac/gamma-cyclodextrin klathrat komponente
NO20004545L (no) FremgangsmÕte for fremstilling av (R)-<alfa>-(2,3- dimetoksyfenyl)-1-[2-(4-fluorofenyl)etyl]-4-piperidinmetanol
HUP0203310A2 (hu) Benzimidazolszármazékot tartalmazó stabil gyógyszerkészítmények és eljárás ezek előállítására
HUP0204430A3 (en) Method for the enzymatic resolution of the racemates of aminomethyl-aryl-cyclohexanol derivatives, the obtained new compounds and pharmaceutical compositions containing thereof

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: EISAI R&D MANAGEMENT CO., LTD., JP

Free format text: FORMER OWNER(S): EISAI CO., LTD., JP

MM4A Lapse of definitive patent protection due to non-payment of fees